OncoOne develops multiple drug modalities that target oxidized macrophage migration inhibitory factor (oxMIF). oxMIF is an isoform of macrophage migration inhibitory factor (MIF) and a new drug target in solid tumor cancer indications. The company says it will pursue treatments for cancer indications with poor prognosis. OncoOne was founded by Randolf Kerschbaumer, PhD, Michael Thiele, PhD and Alexander Schinagl, PhD. The initial funding is intended to enable development of these therapeutic solutions. The company is based in Klosterneuburg, Austria.

Total raised

$14M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2020